Published in Can J Cardiol on June 01, 2003
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med (2007) 7.99
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ (2003) 3.85
Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med (2007) 3.69
Results of the Ontario survey on the prevalence and control of hypertension. CMAJ (2008) 2.88
Cost-effectiveness of epinephrine and dexamethasone in children with bronchiolitis. Pediatrics (2010) 2.68
Use of the 2008 basel consensus statements to assess, realign, and monitor pharmacy practice at a tertiary care hospital in northern Uganda: illustrative case study. Can J Hosp Pharm (2013) 2.53
Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ (2011) 2.34
The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med (2006) 2.16
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med (2009) 1.85
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Wage losses in the year after breast cancer: extent and determinants among Canadian women. J Natl Cancer Inst (2008) 1.80
Evaluating the Risk of Re-identification of Patients from Hospital Prescription Records. Can J Hosp Pharm (2009) 1.78
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrol Dial Transplant (2007) 1.67
Estimating quality of life in acute venous thrombosis. JAMA Intern Med (2013) 1.65
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
Barriers and remaining questions on assessment of absolute cardiovascular risk as a starting point for interventions to reduce cardiovascular risk. J Hypertens (2006) 1.48
A Pilot Comparative Study of the Clarity and Assessability of the Drug Management Standards of Accreditation Canada and the US Joint Commission. Can J Hosp Pharm (2011) 1.44
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. Am J Med (2003) 1.43
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Adherence to lipid-lowering drug therapy among members of the Canadian Forces. Mil Med (2008) 1.38
The bedside investigation of pulmonary embolism diagnosis study: a double-blind randomized controlled trial comparing combinations of 3 bedside tests vs ventilation-perfusion scan for the initial investigation of suspected pulmonary embolism. Arch Intern Med (2006) 1.29
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular disease. Pharmacotherapy (2004) 1.24
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol (2005) 1.19
Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy (2005) 1.17
Age, gender, and urban-rural differences in the correlates of physical activity. Prev Med (2004) 1.15
Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP). Am J Hypertens (2008) 1.15
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med (2003) 1.08
Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer. J Clin Oncol (2011) 1.03
Risk factors for genital chlamydial infection. Can J Infect Dis (2002) 1.00
Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ (2005) 1.00
Effect of exercise training on physical fitness in type II diabetes mellitus. Med Sci Sports Exerc (2010) 1.00
Discussing coronary risk with patients to improve blood pressure treatment: secondary results from the CHECK-UP study. J Gen Intern Med (2008) 0.99
The analysis by Manuel and colleagues creates controversy with headlines, not data. CMAJ (2005) 0.97
Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO). Can J Cardiol (2005) 0.94
Restricted driver licensing for medical impairments: does it work? CMAJ (2002) 0.91
Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Can J Cardiol (2008) 0.91
Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy. Can J Clin Pharmacol (2003) 0.90
Ottawa panel evidence-based clinical practice guidelines for aerobic walking programs in the management of osteoarthritis. Arch Phys Med Rehabil (2012) 0.90
Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? J Urol (2006) 0.89
How Many Words Does a Picture Really Tell? Cross-sectional Descriptive Study of Pictogram Evaluation by Youth. Can J Hosp Pharm (2013) 0.87
What is the feasibility of implementing effective sodium reduction strategies to treat hypertension in primary care settings? A systematic review. J Hypertens (2014) 0.87
Taste and/or Odour Disturbances in Pediatric Patients Undergoing IV Flush with Normal Saline Administered by Prefilled Syringe. Can J Hosp Pharm (2012) 0.86
Health-related quality of life in cardiac patients with dyslipidemia and hypertension. Qual Life Res (2004) 0.86
Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg (2007) 0.85
Validity of information obtained from a method for estimating cancer costs from the perspective of patients and caregivers. Qual Life Res (2010) 0.84
(Correcting) misdiagnoses of asthma: a cost effectiveness analysis. BMC Pulm Med (2011) 0.84
Estimating the benefits of patient and physician adherence to cardiovascular prevention guidelines: the MyHealthCheckup Survey. Can J Cardiol (2011) 0.84
Out-of-pocket costs in the year after early breast cancer among Canadian women and spouses. J Natl Cancer Inst (2013) 0.84
Comparing the benefits of diet and exercise in the treatment of dyslipidemia. Prev Med (2002) 0.84
Standard concentrations of high-alert drug infusions across paediatric acute care. Paediatr Child Health (2008) 0.83
A comparative cost-minimization analysis of providing paediatric palliative respite care before and after the opening of services at a paediatric hospice. Healthc Manage Forum (2010) 0.83
Buffered lidocaine hydrochloride solution with and without epinephrine: stability in polypropylene syringes. Can J Hosp Pharm (2009) 0.83
Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia? Can J Cardiol (2007) 0.83
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension (2004) 0.83
Occupational exposure to cyclophosphamide in nurses at a single center. J Occup Environ Med (2014) 0.82
Prospective evaluation of preferences and quality of life in women with hip fractures. J Rheumatol (2005) 0.82
The association between sleep disturbance, depressive symptoms, and health-related quality of life among cardiac rehabilitation participants. J Cardiopulm Rehabil Prev (2014) 0.81
Income inequality and health in Ontario: a multilevel analysis. Can J Public Health (2005) 0.81
Design and validation of pictograms in a pediatric anaphylaxis action plan. Pediatr Allergy Immunol (2015) 0.81
Impact of modified glucose target and exercise interventions on vascular risk factors. Diabetes Res Clin Pract (2005) 0.81
Volunteer satisfaction and program evaluation at a pediatric hospice. J Palliat Med (2012) 0.80
Off-label drug use in pediatric anesthesia and intensive care according to official and pediatric reference formularies. Can J Anaesth (2010) 0.80
Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol. Epidemiology (2003) 0.80
The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788]. Implement Sci (2010) 0.80
Pharmacoeconomics of long-term treatment of rheumatoid arthritis. Expert Opin Pharmacother (2002) 0.80
Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol (2009) 0.80
Drug use evaluation of oral antibiotics prescribed in the ambulatory care settings in the Canadian armed forces. Can J Clin Pharmacol (2003) 0.79
Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis. Chronic Dis Can (2003) 0.78
Evaluation, modification and validation of a set of asthma illustrations in children with chronic asthma in the emergency department. Can Respir J (2012) 0.78
Dietary counselling for dyslipidemia in primary care: results of a randomized trial. Can J Diet Pract Res (2002) 0.78
Evaluation of pharmacist-managed nonprescription drug benefit for Canadian military personnel. J Am Pharm Assoc (2003) (2005) 0.78
Pretreatment of infant formula with sodium polystyrene sulfonate : focus on optimal amount and contact time. Paediatr Drugs (2013) 0.78
Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: results of a randomized trial. Am Heart J (2005) 0.78
Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study--observational. Curr Med Res Opin (2009) 0.77
Obesity and the prevalence and management of hypertension in Ontario, Canada. Am J Hypertens (2010) 0.77
Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate? Can J Cardiol (2008) 0.76
Cost-effectiveness of lipid-lowering treatment according to lipid level. Can J Cardiol (2005) 0.76
Association between antidepressant use and prescribing of gastric acid suppressants. Can J Psychiatry (2006) 0.76
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model. Am J Cardiovasc Drugs (2007) 0.76
Stability of celecoxib oral suspension. Can J Hosp Pharm (2009) 0.76
In vitro study of esomeprazole sachet suspension administered via enteral feeding tubes. Can J Hosp Pharm (2009) 0.75
[Not Available]. Can J Hosp Pharm (2012) 0.75
Treatment cost effectiveness in acute otitis media: A watch-and-wait approach versus amoxicillin. Paediatr Child Health (2010) 0.75
Review of prescribing practices for intermittent bolus administration of morphine. Can J Hosp Pharm (2011) 0.75
Wasted medications, wasted resource. Can Pharm J (Ott) (2013) 0.75